S. Albert a, ⁎, C. Le tourneau b, M. Gatineau c, J. Delord d, J. Fayette e, C. Dreyer f, A. Tijeras-Raballand g, M. Granier h, B. Chibaudel i, A. Hadengue i, N. Aissat i, K. Slimane j, E. Raymond k, B. Barry a, S. Faivre k
a Inserm U773, chirurgie cervicofaciale, hôpital Bichat, AP–HP, Paris-7, Paris, France
b Service d’oncologie, institut Curie, Paris, France
c Hopital Saint-Joseph, Paris, France
d Institut Claudius-Regaud, Toulouse, France
e Centre Léon-Bérard, Lyon, France
f Department of Medical Oncology, Beaujon University Hospital, Clichy, France
g Inserm U773, AAREC Filia Research, Boulogne-Billancourt, Clichy, France
h AAREC Filia Research, Boulogne-Billancourt, Clichy, France
i GERCOR, Paris, France
j Novartis Pharma SAS, Rueil-Malmaison, France
k Inserm U728, cancérologie, Beaujon, AP–HP, Clichy, France